Hematopoiesis is the process by which daughter cells of multipotential, self-renewing stem cells progress along differentiation pathways to become progressively more committed to specific lineages while losing their self-renewal capacity. Leucopenia and thrombocytopenia after ionising radiation exposure are due largely to injury to stem cells and progenitors in the hematopoietic tissue of the bone marrow; and in mice, the spleen. Recovery depends on the ability of the remaining stem cells and progenitors to proliferate and differentiate sufficiently to reconstitute the immune system before it is challenged by potential microorganisms and lethal infections occur. This mini review discusses various approaches to the mobilisation of progenitors and their utility as a bridging therapy for radiation casualties.
INTRODUCTION
The detonation of a nuclear device through either military or terrorist action would lead to a mass-casualty scenario involving victims with varying degrees of exposure to ionising radiation.
1,2 Victims exposed to high doses of ionising radiation will present with the signs and symptoms of various degrees of acute radiation syndrome (ARS). ARS describes three distinct dose-dependent syndromes: hematopoietic, gastrointestinal (GIS), and the central nervous syndrome (CNS); CNS being the most severe. Prognosis for victims who have received a gastrointestinal or CNS dose, even with supportive care, is poor. Moderate exposure (2 to 4 Gy) will lead to the more medically manageable hematopoietic syndrome, characterised by depletion of hematopoietic stem cells (HSC) in the bone marrow 3 . Over the last 30 years, the expected outcome for accidental exposure to high doses of ionising radiation has been very poor 4 . For radiation-induced neutropenia, often observed in the accidental-exposure scenario, currently there is only one treatment protocol. There are two components to this protocol: aggressive supportive care, and the administration of granulopoietic cytokines as soon as possible. There is a substantial preclinical database demonstrating the effect of these growth factors in stimulating granulopoiesis and survival after lethal doses of radiation; however, the outcome is far from satisfactory. Various investigators have been evaluating combined regimens of different cytokines in experimental models 5 . Development of countermeasures to ionising radiation, both radioprotectants and mitigators, has been identified by the US Department of Homeland Security as the highest priority in preparation for a terrorist attacks 6 . Currently, there are no suitable countermeasures against nuclear/ radiological hazards for military or civilian personnel, other than the limited hazard of internalised radioisotopes. Any radiation exposure can significantly influence operations of our military, national guards, and first responders. The problem has become more acute in recent times given the unpredictable nature of attacks. The US Department of Defense, as indicated in a current Defense Technical Objective that lists developing medical countermeasures to radiation exposure as a top priority and cites both early and late occurring health effects as major concerns, has recognised this deficiency. The US Army Qualitative Research Requirements rank and prioritise these radiation exposureassociated health effects as being very important. Furthermore, the US Navy has identified enhanced treatment regimens for radiation injuries and protection against radiation injury as priority needs. These concerns reinforce the urgent need to develop an appropriate modality to sustain the war-fighting capabilities of our military. Strategically, first responders and medical providers should have an array of radiation countermeasures at their disposal 7 . With this in mind, considerable progress has been made in the development of radioprotectants 8, 9 . There are several radiation countermeasures at different stages of development [10] [11] [12] [13] [14] 9, [15] [16] [17] . The human hematopoietic system is highly susceptible to radiation injury. During any ionising radiation exposure scenario, a majority of victims will be exposed to a sufficient dose to possibly impair but not entirely ablate hematopoietic (bone marrow) function. As such, these victims would likely recover from their injuries but would have faced a period of 3060 days during which they would have difficulty fighting infections, uncontrolled bleeding and anemia 2 . Therefore, in order to keep these compromised individuals alive, substantial supportive care must be provided, at least to the point of partial recovery of their hematopoietic system.
Effective post-exposure treatments are critical as these serve to broaden the utility of first responders for the effective rescue and salvage of the more critically injured victims of a given radiological disaster. Acute ionising radiation injuries are managed by treating the developing symptoms with blood transfusions, electrolytes, and antibiotics. If the estimated exposure is substantial (e.g., 2 Gy or more) with markedly severe cytopenias (lymphopenia), it is recommended that cytokine therapy be commenced shortly after exposure 18, 19 . For patients who do not respond to cytokine therapy, the transplantation of HSC remains an option 20, 21 .
USE OF PROGENITORS IN RADIATION CASUALTIES
Weissman and colleagues first isolated a population of highly enriched mouse HSC through extensive phenotypic cell surface analysis and in vitro and in vivo functional assays for stem cell activity 22 . Additional investigations have shown that the HSC population is functionally heterogeneous, which comprised a lineage of cells demonstrating a continual loss of self-renewal. The longterm reconstituting HSC (LT-HSC) provide life-long hematopoiesis, ultimately giving rise to mature cells of all lineages. This is the only hematopoietic stem or progenitor cell that durably engrafts, and is the functional component in bone marrow transplantation.
Directly downstream of the LT-HSC in the hematopoietic maturation pathway are transiently reconstituting HSC with identical multilineage potential but which possess little or no self-renewal capacity 23 . These are termed shortterm reconstituting HSC (ST-HSC) and multipotent progenitors (MPP). While these HSC provide only a transient repopulating ability, these are equally radioprotective when myeloablation is not complete 23 . The earliest branch points between the lymphoid and myelo-erythroid lineages are defined as the oligopotent progenitors; the common lymphoid progenitor (CLP) and the common myeloid progenitor (CMP). Like the HSC, both the CLP and CMP have been isolated through techniques that use prospective identification via cell surface markers, flow cytometry, and an array of functional assays 24, 25 . From the CMP, the myelo-erythroid lineages are further defined by discrete progenitors: the granulocyte/macrophage progenitor (GMP) and the megakaryocyte/erythrocyte progenitor (MEP). None of these cells (the CLP, the CMP and their downstream progenitorsGMP, MEP) possesses extended self-renewal ability. However, progenitor cells are capable of partially restoring functional hematopoiesis for a limited period of time [26] [27] [28] . A combination of CMP/ GMP isolated from the bone marrow has been shown to protect myeloablated mice from otherwise lethal doses of pathogenic fungus or bacteria in syngeneic and allogeneic mouse models 26, 29, 30 . Furthermore, purified populations of CMP or MEP but not GMP protect lethally irradiated congenic mice from death in a dose-dependent manner 28 . Mice receiving a minimal lethal dose of radiation typically die within 12-18 days from bone marrow failure. CMP and MEP purified from mouse bone marrow were found to protect these mice for this critical period post-irradiation 28 . All mice surviving for 30 days went on to survive longer than 6 months and possessed only host-derived hematopoiesis after 30 days. These findings illustrate that if a transient bridging therapy is delivered providing needed granulocytes, red blood cells, and platelets during the critical period of bone marrow failure, host HSC surviving radioablation may provide recovery as a result of functional hematopoiesis.
On the molecular level, much is being learned about signals that regulate self-renewal, proliferation, and differentiation of hematopoietic stem and progenitor cells 31, 32 . Murine CD117 + (or cKit + ) lineage negative cells are indeed multipotential and primitive in nature, with strong repopulating and self-renewing capacities, as are the equivalent CD34 + lineage negative cells in humans, and are used to quantitate stem cell content in transfused blood/marrow volumes. Because of the complex protein and cellular interactions involved, identification of the preferred mobilisation method requires assessment of the qualities of cells mobilised with different agents.
MOBILISATION OF PROGENITORS BY
GRANULOCYTE COLONY STIMULATING FACTOR Colony-stimulating factors (CSF) are a family of glycoproteins that control the functional activity, survival, proliferation, and differentiation of myeloid hematopoietic cells 33 ( Fig. 1) . These cytokines are involved at various stages of the proliferation and differentiation processes, from the proliferation and survival of the pluripotent stem cells to the final differentiation and mobilisation of mature granulocytes and monocytes from the marrow to the blood. Commercially available forms of G-CSF include filgrastim, an Escherichia coli-derived recombinant protein, and lenograstim, a glycosylated form of G-CSF produced in Chinese hamster ovary cell lines 34 . Hematopoietic stem and progenitor cells normally reside in the bone marrow but can be rapidly released into the peripheral blood in response to a wide variety of stimuli 35 . Mobilisation of stem cells can be so effective that a sufficient number of cells can be harvested for use in stem cell transplantation. In allogeneic stem cell transplantation, G-CSF-mobilised peripheral blood stem and progenitor cells now are replacing marrow-derived hematopoietic stem and progenitors as a stem cell source 36 . Because of the ease with which blood stem cells can be obtained, and because of their potentially superior engraftment characteristics compared with marrow-derived stem cells, at present most stem-cell transplantations in human beings are performed using blood-derived grafts 37 . The main advantages of using peripheral blood progenitor cells in place of bone marrow in clinical transplantation protocols include the more rapid hematopoietic recovery of transplanted recipients, the ability to collect the hematopoietic graft less invasively, and the feasibility of harvesting the graft from patients with bone marrow fibrosis 38 . Previous studies have shown that the administration of hematopoietic growth factors, either alone or in combination with cytotoxic drugs, efficiently mobilises hematopoietic progenitors from bone marrow 39 . Although several growth factors are capable of inducing mobilisation of hematopoietic progenitors, G-CSF at present is one of the most efficient mobilising molecules used both in experimental models and clinical protocols 40 . The efficiency of G-CSF to mobilise bone marrow precursors and long-term repopulating cells initially was shown in early preclinical studies 41 . Administration of G-CSF stimulates hyperplasia within the bone marrow as well as a reduction in stromal cell-derived factor-1 (SDF-1; also called CXCL12) mRNA expression, and an increase in matrix metalloproteinase-9-dependent degradation of existing SDF-1 [42] [43] [44] . The latter molecular events would serve to enhance the mobilisation process via a lessening of binding affinities of resident HSCs to the hematopoieticallyinducive marrow stroma.
Overall, use of exogenous G-CSF is associated with various disadvantages, such as occasional severe toxic side effects; drug instability at environmental temperatures, requiring refrigeration throughout the supply chain; and high cost.
AMD3100 (PLERIXAFORMOZOBIL) AS AN AGENT FOR MOBILISING PROGENITORS
The ability of AMD3100 to increase the number of circulating white blood cells was first discovered during clinical trials as an anti-HIV drug candidate 45 . A bicyclam, AMD3100 is composed of two cyclam units linked by an aromatic linker. Commercially known as Plerixafor or Mozobil, AMD3100 is a powerful CXCR4 (a CXC chemokine receptor) antagonist that disrupts interactions between CXCR4 and SDF-1. AMD3100 chemokine antagonist interactions promote the migration of CD34 + HSC from bone marrow into peripheral blood, where these can be collected for use in autologous hematopoietic stem cell transplant (HSCT) (Fig. 1) . In combination with G-CSF, AMD3100 has been approved to mobilise HSC for autologous HSCT in patients with nonHodgkins lymphoma or multiple myeloma 36 . Plerixafor is a reversible, pure antagonist of CXCR4 that competes with SDF-1 46 . It disrupts the interactions between CXCR4 on CD34 + HSC and SDF-1 on bone marrow stromal cells, essentially blocking the chemotactic actions of SDF-1 47 .
This displacement of previously anchored CD34 + HSC causes their release from stromal cells, allowing their subsequent migration from the bone marrow into the peripheral blood 48, 49 . The ability of plerixafor to facilitate this movement was first observed in studies evaluating the agents potential antiviral effects 50 . Plerixafor has not been found to interact with other chemokine receptors 49 . Although both G-CSF and plerixafor have the ability to mobilise HSC, a study of the mobilisation products of plerixafor has suggested that this agent acts on a more primitive subsets of CD34 + HSC than does G-CSF. The need to better understand the hematopoietic repopulating ability of plerixafor has led to additional studies to characterise the quality of the cells being mobilised. The difference in the mechanisms by which G-CSF and plerixafor mobilise HSC also suggests that different subsets of HSC may be mobilised by each agent and a potential for mobilising a better quality of HSC exists when the two agents are used in combination compared with either agent alone 51 . The combination of G-CSF and plerixafor has been found to facilitate HSC mobilisation in patients with multiple myeloma, non-Hodgkins lymphoma, and Hodgkins lymphoma 51 .
TOCOPHEROL SUCCINATE
Vitamin E is a generic term used for eight naturally occurring tocopherols and tocotrienols (a, b, g, d) as well as their derivatives 52 . These analogs are known as tocols; a-tocopherol has been the focus of research because it is the predominant form in human beings and animal tissues. In addition, it is by far the most bioactive form based on the rat fetal resorption test, which is the classical assay for vitamins. Recently, the authors investigated the radioprotective efficacy of a-tocopherol succinate (TS) and their results indicate that TS is effective in protecting mice when given 24 h before irradiation 53 (dose reduction factor 1.28). TS also modulates the expression of various antioxidant genes and helps in hematopoietic recovery 54 . The authors demonstrated that TS stimulates G-CSF production and showed that TS-mediated protection can be neutralised by administration of G-CSF antibody 53, 55, 56 . The authors hypothesised that TS mobilises progenitor cells into the peripheral circulation. Therefore, they evaluated the efficacy of whole blood obtained from TS-treated mice for protection against g-irradiation to compare with blood obtained from G-CSF-treated mice. All mice, that were irradiated but received no transfusion, died. Survival was significantly higher in the groups where mice received blood either from TS-or G-CSF-treated donors 57 . The authors hypothesised that the early progenitors mobilised by TS could be used to treat injuries due to ionising radiation. Therefore, they evaluated the efficacy of peripheral blood mononuclear cells (PBMC) obtained from TS-injected mice for protection against g-radiation exposure. A significant survival benefit was afforded to groups that received from TS donors either 0.5 million or 2 million cells at 2 h or 24 h post-irradiation compared to untreated irradiated mice 57 . When both TS and AMD3100 were administered, they observed very high HSC mobilisation in peripheral blood. Their results demonstrate enhancement of lin -Sca-1 (Ly-6A/E), c-Kit (CD117) as well as double positive cells (Sca-1, c-Kit) in response to TS/AMD3100 administration 56 . HSC mobilisation by TS was comparable to that achieved by G-CSF.
Compared to G-CSF and other agents used for mobilising progenitors (AMD3100Mozobil/plerixafor), TS is a stable, inexpensive, and well-tolerated product that induces endogenous G-CSF. The authors believe that TS is highly efficient and will outperform exogenously administered G-CSF in the clinic, in terms of mobilising high quality, regenerative marrow progenitors into the blood for subsequent collection, transfusion, and effective therapy of various disease states associated with acute immunosuppression. The authors conclude that TS as an effective HSC mobiliser that might well offer a number of very practical, very significant advantages (i.e., less expense, more stable, simpler to administer, etc.) over the conventionally used recombinant growth factor, recombinant human G-cSF: however, advanced preclinical studies using large animal studies, with subsequent clinical trials using volunteers will be needed prior to making any claims of TSs potential clinical utility.
CONCLUSIONS
Victims of a terrorist attack presenting with the hematopoietic syndrome resulting from exposure to excessive levels of ionising radiation will succumb to sepsis if not adequately treated. Survival probability is increased substantially if the victims immune system is allowed to recover before sepsis sets in. Preclinical development of a new bridging therapy that will allow the victims immune system to recover from damage caused by ionising radiation has been reported. TS has been found, using a well-defined, preclinical murine model of acute ionising radiation injury, to be a welltolerated and promising radiation countermeasure. TS is inexpensive and induces high levels of G-CSF in circulation within 24 h of subcutaneous administration, leading to mobilisation of marrow progenitors into peripheral blood. Transfusion of frozen and stored whole blood, or selectively enriched progenitorial cell fractions from TS-treated donor mice, into lethally ionising radiation-exposed recipients can provide enhanced hematopoietic repair and recovery and, in turn, extend survival. Further preclinical work and refinements, as well as subsequent clinical translation of the TS-blood progenitor mobilisation and autologous blood infusion protocol, might provide a simpler, improved protocol in clinical management of individuals suffering from high ionising radiation dose-mediated ARS.
Recently, other investigators have initiated such studies. One group has developed a cellular therapy that contains Bone Marrow human progenitor cells. This group (Cellerant Therapeutics, San Carlos, CA) has been awarded a $153 million grant from the Biomedical Advanced Research and Development Authority (BARDA) to develop CLT-008 as a cellular therapy for treating the hematopoietic syndrome observed after acute exposure to ionising radiation 58 . Upon transfusion of CLT-008 into the irradiated victim, the progenitor cells will have the ability to mature into granulocytes, platelets, and erythrocytes. 
